NPI: 1700823051 · PHOENIX, AZ 85014 · Ophthalmology Physician · NPI assigned 06/02/2006
Authorized official BROOKFIELD, ARTHUR controls 20+ related entities in our dataset. Read more
| Authorized Official | BROOKFIELD, ARTHUR (CFO) |
| NPI Enumeration Date | 06/02/2006 |
Other providers sharing the same authorized official: BROOKFIELD, ARTHUR
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 12,250 | $382K |
| 2019 | 11,778 | $460K |
| 2020 | 10,973 | $481K |
| 2021 | 16,467 | $956K |
| 2022 | 17,463 | $1.27M |
| 2023 | 17,135 | $1.59M |
| 2024 | 10,661 | $1.03M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 67028 | Intravitreal injection of a pharmacologic agent | 24,565 | 22,443 | $1.65M |
| J0178 | Injection, aflibercept, 1 mg | 810 | 755 | $981K |
| 92134 | 36,584 | 34,193 | $862K | |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | 8,151 | 7,740 | $677K |
| J7999 | Compounded drug, not otherwise classified | 8,229 | 7,053 | $500K |
| J2778 | Injection, ranibizumab, 0.1 mg | 420 | 393 | $330K |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | 4,086 | 3,683 | $241K |
| J9035 | Injection, bevacizumab, 10 mg | 3,401 | 3,086 | $219K |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 4,022 | 3,677 | $165K |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | 308 | 301 | $134K |
| 99204 | Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 1,312 | 1,205 | $89K |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | 556 | 548 | $77K |
| 67210 | 190 | 152 | $55K | |
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2,203 | 2,012 | $52K |
| 92235 | 614 | 583 | $45K | |
| J2777 | Injection, faricimab-svoa, 0.1 mg | 33 | 32 | $44K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 344 | 319 | $15K |
| 92250 | 538 | 509 | $14K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 262 | 193 | $6K |
| 99203 | Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 99 | 91 | $5K |